Raymond James Financial
VTGN icon

Raymond James Financial’s VistaGen Therapeutics VTGN Stock Holding History

Raymond James Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.36K Sell
14,851
-33
-0.2% -$20 ﹤0.01% 5390
2026
Q1 		$8.51K Buy
+14,884
New +$9.04K ﹤0.01% 5260
2025
Q3 		– Sell
-6,410
Closed -$12.8K – 6755
2025
Q2 		$12.8K Buy
+6,410
New +$14.6K ﹤0.01% 5805

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Raymond James Financial's VTGN Position: Q2 2026 in Review

Raymond James Financial reduced its VistaGen Therapeutics (VTGN) stake by 0.22% in Q2 2026, selling an estimated $20 and leaving 14,851 shares worth $3.36K. The position accounts for ﹤0.01% of the portfolio, ranked #5390.

Raymond James Financial first reported a position in VTGN in Q2 2025 and has held it in 3 quarters since. The position peaked at $12.8K in Q2 2025. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Raymond James Financial held 14,851 shares of VistaGen Therapeutics worth $3.36K as of Q2 2026.
  • Raymond James Financial sold 33 VistaGen Therapeutics shares in Q2 2026, an estimated $20.
  • VistaGen Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5390 holding.
  • Raymond James Financial first reported a position in VistaGen Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's VistaGen Therapeutics position peaked at $12.8K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.